ONCOLOGY
Rigorous science is at the core of Incyte. The breadth of our portfolio and its balance between early- and later-stage candidates is unique for a company of our size. Our research and development in Oncology includes targeted and immunotherapies, including small molecules, monoclonal antibodies and bispecific antibodies, providing us with the opportunity to explore combinations of therapies from both within and beyond our own portfolio.